- Home
- ABVC vs AFMD Comparison
ABVC vs AFMD Comparison
Compare ABVC & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- AFMD
- Stock Information
- Founded
- ABVC 2015
- AFMD 2000
- Country
- ABVC United States
- AFMD Germany
- Employees
- ABVC N/A
- AFMD N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- AFMD Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- AFMD Health Care
- Exchange
- ABVC Nasdaq
- AFMD Nasdaq
- Market Cap
- ABVC 16.7M
- AFMD 14.5M
- IPO Year
- ABVC N/A
- AFMD 2014
- Fundamental
- Price
- ABVC $0.93
- AFMD $0.64
- Analyst Decision
- ABVC
- AFMD Strong Buy
- Analyst Count
- ABVC 0
- AFMD 5
- Target Price
- ABVC N/A
- AFMD $13.50
- AVG Volume (30 Days)
- ABVC 282.7K
- AFMD 87.4K
- Earning Date
- ABVC 05-16-2025
- AFMD 04-08-2025
- Dividend Yield
- ABVC N/A
- AFMD N/A
- EPS Growth
- ABVC N/A
- AFMD N/A
- EPS
- ABVC N/A
- AFMD N/A
- Revenue
- ABVC $509,788.00
- AFMD $6,287,085.00
- Revenue This Year
- ABVC N/A
- AFMD N/A
- Revenue Next Year
- ABVC N/A
- AFMD $225.65
- P/E Ratio
- ABVC N/A
- AFMD N/A
- Revenue Growth
- ABVC N/A
- AFMD N/A
- 52 Week Low
- ABVC $0.40
- AFMD $0.69
- 52 Week High
- ABVC $1.73
- AFMD $8.95
- Technical
- Relative Strength Index (RSI)
- ABVC 68.26
- AFMD 18.63
- Support Level
- ABVC $0.65
- AFMD $0.85
- Resistance Level
- ABVC $1.40
- AFMD $0.79
- Average True Range (ATR)
- ABVC 0.10
- AFMD 0.06
- MACD
- ABVC 0.05
- AFMD -0.01
- Stochastic Oscillator
- ABVC 62.03
- AFMD 0.00
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.